title: Intervention with the aldose reductase inhibitor, tolrestat, in renal and retinal lesions of streptozotocin-diabetic rats.
abstract: The progressive increase in urinary albumin excretion, which precedes the development of diabetic nephropathy, can be prevented in diabetic rats if the aldose reductase inhibitor, tolrestat, is administered at the initiation and throughout the duration of hyperglycaemia. We therefore determined the ability of tolrestat to intervene in the further progression of already established urinary albumin excretion of streptozotocin-diabetic female Wistar rats. Two months after streptozotocin injection, diabetic rats were grouped as low-urinary albumin excretion (0.2-1.0 mg albumin/day) or high-urinary albumin excretion (1.9-5.9 mg albumin/day), at which time tolrestat intervention (25 mg/kg per day) was begun for half of the diabetic rats in each urinary albumin excretion group. After six months of treatment tolrestat caused a significant reduction in the urinary albumin excretion rate of the low-urinary albumin excretion group only. The diabetes-induced rise of total urinary protein in both groups was significantly reduced by tolrestat. Furthermore, the diabetes-induced increase (49%) in the thickness of the basement membranes of retinal capillaries from the outer plexiform layer was significantly diminished by tolrestat administration. In conclusion, intervention therapy with the aldose reductase inhibitor, tolrestat, can reduce the progression of urinary albumin excretion and retinal basement membrane thickening in long-term diabetic rats.
authors.affiliation: Wyeth-Ayerst Research, Princeton, New Jersey.
authors.forename: M L
authors.initials: ML
authors.lastname: McCaleb
authors.forename: M L
authors.initials: ML
authors.lastname: McKean
authors.forename: T C
authors.initials: TC
authors.lastname: Hohman
authors.forename: N
authors.initials: N
authors.lastname: Laver
authors.forename: W G
authors.initials: WG
authors.lastname: Robison
mesh_terms: D000419:Albuminuria; D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D000818:Animals; D001485:Basement Membrane / Q000473:pathology; D001786:Blood Glucose / Q000378:metabolism; D001806:Blood Urea Nitrogen; D002196:Capillaries / Q000473:pathology; D003404:Creatinine / Q000097:blood / Q000652:urine; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D003929:Diabetic Neuropathies / Q000517:prevention & control*; D003930:Diabetic Retinopathy / Q000473:pathology / Q000517:prevention & control*; D005260:Female; D006029:Glycosuria; D009131:Muscle, Smooth, Vascular / Q000473:pathology; D009281:Naphthalenes / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains; D012160:Retina / Q000473:pathology; D014280:Triglycerides / Q000097:blood
chemical_list: D001786:Blood Glucose; D009281:Naphthalenes; D014280:Triglycerides; C040550:tolrestat; D003404:Creatinine; D000449:Aldehyde Reductase